Hepatic drug delivery and gene therapy

Hepatology

Volumn 25, Issue 2, 1997, Pages 484-491

  Zern, Mark A ^a   Kresina, Thomas F ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; MICROSPHERE; PRODRUG; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; BASE MISPAIRING; CARCINOGENESIS; DRUG DELIVERY SYSTEM; GASTROINTESTINAL DISEASE; GENE THERAPY; GENE TRANSFER; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIGAND BINDING; LIVER DISEASE; METABOLIC DISORDER; PRIORITY JOURNAL; RETROVIRUS; REVIEW; STEM CELL;

EID: 0031014778     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250238     Document Type: Review

References (71)

1. Bryan T, Reddel B. SV40-induced immortalization of human cells. Crit Rev Oncog 1994;5:331-357.
2. Mortimer E Jr, Lepow M, Gold E, Robbins F, Burton G, Fraumeni J. Long-term follow-up of persons inadvertently inoculated with SV40 as neonates. N Engl J Med 1981;305:1517-1518.
3. Yao T, Degli Esposti S, Huang L, Arnon R, Spangenberger A, Zern MA. Inhibition of carbon tetrachloride-induced liver injury by liposomes containing vitamin E. Am J Physiol 1994;30:G476-G484.
4. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991;179:280-285.
5. Gao X, Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry 1996;35:1027-1036.
6. Zhou F, Huang L. Delivery of protein antigen to the major histocompatibility complex class I-restricted antigen presentation pathway. J Drug Target 1995;3:91-109.
7. Farhood H, Gao X, Barsoum J, Huang L. Codelivery to mammalian cells of a transcriptional factor with cis-acting element using cationic liposomes. Anal Biochem 1995;225:89-93.
8. DeSouza P, D'Souza MJ. Formulation and in vitro uptake studies of polylactic co-glycolic acid microspheres and amino modified latex particles into rat peritoneal macrophages. Pharm Res 1990;7:S162-S169.
9. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994;91:8302-8306.
10. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995;55:4808-4812.
11. Zhao X, Wong T, Batten B. Protein transfer into mouse eggs by the electric field method. Techn J Method Cell Mol Biol 1989;1:37-42.
12. Kotani H, Sekiguchi MJ, Kmiec EB. Genetic recombination of nucleosomal templates is mediated by transcription. Mol Gen Genet 1994;244:410-419.
13. Kmiec EB, Cole AD, Holloman WK. Homologous pairing promoted by the Rec2 gene product. Mol Cell Biol 1994;14:7163-7172.
14. Kmiec EB. Genomic targeting and genetic conversion in cancer therapy. Semin Oncol 1996;23:188-193.
15. Dutta S, Gerhold D, Kmiec EB. Assembly of nucleosomal DNA in a cell-free extract from wild-type and top 1-strains of Ustilago maydis. Mol Gen Genet 1995;248:675-685.
16. Yuan F, Baxter LT, Jain RK. Pharmacokinetic analysis of two-step approach using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991;51:3119-3130.
17. Baxter LT, Yuan F, Jain RK. Pharmacokinetic analysis of the perivascular distributions of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res 1992;52:5838-5844.
18. Baxter LT, Jain RK. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Br J Cancer 1996;73:447-456.
19. Netti PA, Baxter LT, Boucher Y, Skalak R, Jain RK. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 1995;55:5451-5458.
20. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 1995;55:4611-4617.
21. Varmus H. Retroviruses. Science 1988;240:1427-1435.
22. Albritton LM, Tseng L, Scadden D, Cunningham JM. A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell 1989;57:659-666.
23. Etienne-Julan M, Roux P, Carillo S, Jeanteur P, Piechaczyk M. The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J Gen Virol 1992;73:3251-3255.
24. Neda H, Wu CH, Wu GY. Chemical modification of an ectotropic virus results in redirection of its target cell specificity. J Biol Chem 1991; 266: 14143-14146.
25. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994;266:1373-1375.
26. Welsh RM, Cooper NR, Jensen FC, Oldstone MBA. Human serum lyses RNA tumor viruses. Nature 1975;257:612-615.
27. Cooper NR, Jensen FC, Raymond MW, Oldstone MBA. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 1976;144:970-976.
28. Evans MJ, Rollins SA, Wolff DW, Rother RP, Squinto SP. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol Immunol 1995;32:1183-1195.
29. Rother RP, Fodor WL, Springhorn JP, Birks CW, Squinto SP. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J Exp Med 1995;182:1345-1355.
30. Fodor WL, Rollins SA, Guilmette ER, Setter E, Squinto SP. A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex. J Immunol 1995; 155:4135-4138.
31. Rother RP, Squinto SP, Mason JM, Rollins SA. Protection of retroviral vector particles in human blood through complement inhibition. Hum Gene Ther 1995;6:429-437.
32. Sigal SH, Brill S, Fiorino A, Reid LM. The liver as a stem cell and lineage system. Am J Physiol 1992;263:G139-G148.
33. Sigal SH, Brill S, Reid LM, Zvibel I, Gupta S, Hixson D, Faris R, et al. Characterization and enrichment of fetal rat hepatoblasts by immunoadsorbtion ("panning") and fluorescence-activated cell sorting. HEPATOLOGY 1994;19:999-1006.
34. Sigal SH, Rajvanshi P, Reid LM, Gupta S. Demonstration of differentiation in hepatocyte progenitor cells using dipeptidyl peptidase IV deficient mutant rats. Cell Mol Biol Res 1995;41:39-47.
35. Malone RW, Hichman MA, Lehmann-Bruinsma K, Sih TR, Walzem R, Carlson DM, Powell JS. Dexamethasone enhancement of gene expression after direct hepatic DNA injection. J Biol Chem 1994;269:29903-29907.
36. Hickman MA, Malone RW, Lehmann-Bruinsma K, Sih TR, Knoell D, Szoka FC, Walzem R, et al. Gene expression following direct injection of DNA into liver. Hum Gene Ther 1994;5:1477-1483.
37. Smith JG, German JB, Hickman MA. Incorporation of tributyrin enhances the expression of a reporter gene in primary and immortalized cell lines. Biotechniques 1995;18:852-855.
38. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994;91:4407-4411.
39. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2a in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A 1994;91:6196-6200.
40. Raper SE, Grossman M, Rader DJ, Thoene JG, Wilson JM. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg 1996;223:116-126.
41. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1995;1:890-893.
42. Yang Y, Xiang Z, Ertl HC, Wilson JM. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A 1995;92:7257-7261.
43. Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996; 334:1185-1187.
44. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM. Recombinant adenovirus deleted of all viral genes for therapy of cystic fibrosis. Virology 1996; 217: 11-22.
45. Fang B, Eisensmith RC, Li XH, Finegold MJ, Woo SL. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther 1994;4: 247-254.
46. Eisensmith RC, Woo SL. Molecular genetics of phenylketonuria: from molecular anthropology to gene therapy. Adv Genet 1995;32:199-271.
47. Chen SH, Chen XH, Wang Y, Kosai K, Woo SL. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995;92:2577-2581.
48. Kay MA, Woo SL. Gene therapy for metabolic disorders. Trends Genet 1994;7:253-257.
49. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989;7:980-990.
50. Burns JC, Freidman T, Driever W, Burrascano M, Yee J-K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentrations to very high titer and efficient gene transfer into mammalian cells and nonmammalian cells. Proc Natl Acad Sci U S A 1993;90:8033-8037.
51. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, During MJ. Long-term gene expression and phenotype correction using adenoassociated virus vectors in the mammalian brain. Nat Genet 1994; 8:148-153.
52. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal RG. In vivo adenovirus-mediated gene transfer of the Escherichia Coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995;6:1055-1063.
53. Crystal RG. In vivo gene therapy: a strategy to use human genes as therapeutics. Trans Am Clin Climatol Assoc 1994;106:87-99.
54. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995;270:404-410.
55. Brody SL, Jaffe HA, Han SK, Wersto RP, Crystal RG. Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum Gene Ther 1994;5:437-447.
56. Wu GY, Zhan P, Sze LL, Rosenberg AR, Wu CH. Incorporation of adenovirus into a ligand-based DNA carrier system results in retention of original receptor specificity and enhances targeted gene expression. J Biol Chem 1994;269:11542-11546.
57. Liang TJ, Makdisi WJ, Sun S, Hasegawa K, Wu GY. Targeted transfection and expression of hepatitis B viral DNA in human hepatoma cells. J Clin Invest 1993;91:1241-1246.
58. Ashwell, Morrell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 1974;41:99-128.
59. Fiume L, Bruna B, Busi C, Mattioli A, Spinosa G. Drug targeting in antiviral chemotherapy: a chemically stable conjugate of 9-b-D-arabinofuranosyladenine 5′-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells. Biochem Pharmacol 1986; 35: 967-972.
60. Ponzetto A, Fiume L, Forzani B, Song SY, Busi C, Mattioli A, Spinelli C, et al. Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than the unconjugated drugs. HEPATOLOGY 1991; 14: 16-24.
61. Wu GY, Wu CH. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 1992;267: 12436-12439.
62. Offensperger WB, Offensperger S, Walter E, Teubner K, Igloi G, Blum HE, Gerok W. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 1993;12:1257-1262.
63. Blum HE. Variants of hepatitis B, C, and D viruses: molecular biology and clinical significance. Digestion 1995;56:85-95.
64. von Weizsacker F, Wieland S, Blum HE. Identification of two separable modules in the duck hepatitis B virus core protein. J Virol 1995; 69:2704-2707.
65. Offensperger WB, Blum HE, Gerok W. Molecular therapeutic strategies in hepatitis B virus infection. Clin Invest 1994;72:737-741.
66. Ilan Y, Nagler A, Shouval D, Ackerstein A, Or R, Kapelushnik J, Adler R, et al. Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors. Clin Exp Immunol 1994; 97: 299-302.
67. Ackerman Z, Wands JR, Gazitt Y, Brechot C, Shouval D. Enhancement of HBsAg detection in serum of patients with chronic liver disease following removal of circulating immune complexes. J Hepatol 1994;20:398-404.
68. Ilan Y, Nagler A, Adler R, Naparstek E, Or R, Slavin S, Brautbar C, et al. Adoptive transfer of immunity to hepatitis B virus after T cell depleted allogeneic bone marrow transplantation. HEPATOLOGY 1993;18:246-252.
69. Shouval D, Adler R, Ilan Y. Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors. HEPATOLOGY 1993;17:955-959.
70. Shouval D, Ilan Y. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol 1995;23:98-101.
71. Nagler A, Ilan Y, Adler R, Or R, Shouval D. Successful immunization of autologous bone marrow transplantation recipients against hepatitis B virus by active vaccination. Bone Marrow Transplant 1995;15:475-478.